Exchange protein directly activated by cAMP 2A (Epac2A)

Exchange protein directly activated by cAMP 2A (Epac2A) is a multidomain guanine nucleotide exchange factor (GEF) that mediates signal transduction downstream of cAMP, functioning primarily to activate the small GTPases Rap1 and Rap2[2][5][7]. Epac2A is encoded by the RAPGEF4 gene located on chromosome 2q31 and is highly expressed in the brain, pancreas, and neuroendocrine tissues, where it plays a central role in the regulation of insulin secretion, cell adhesion, and neuronal signaling[5][7][8]. Structurally, Epac2A contains two cyclic nucleotide-binding domains (cNBD-A and cNBD-B), a DEP domain for membrane targeting, and a C-terminal catalytic region with CDC25 homology (responsible for nucleotide exchange), a Ras exchange motif, and a Ras association domain[1][2][5]. Binding of cAMP to Epac2A triggers conformational changes that relieve autoinhibition, allowing the catalytic domain to activate Rap proteins. Epac2A is a therapeutic target for metabolic, neurological, and proliferative diseases, with pharmacology including both agonists (such as incretins and sulfonylureas) and isoform-specific antagonists[6][7][8]. Its critical role in insulin secretion makes it especially relevant in diabetes pharmacotherapy, but its wider expression pattern also links it to other pathologies, including neurodegeneration and cancer[2][7].

Other names

Epac2cAMP-regulated guanine nucleotide exchange factor IIRAPGEF4Exchange protein directly activated by cAMP 2cAMP-GEFII

Activation by cAMP leads to a conformational change, exposing the catalytic domain to activate Rap1/Rap2. Sulfonylureas enhance Epac2A signaling to augment insulin secretion independent of ATP-sensitive potassium channel closure. Specific small-molecule antagonists inhibit by stabilizing the protein's autoinhibitory conformation.